Significant improvement in dry eye symptoms New mechanism of action eye drops Phase 2 clinical results are positive

Recently, Aldeyra Therapeutics announced positive top-line data from a Phase 2 clinical trial of its investigational therapy reproxalap eye drops in patients with dry eye disease

In patients with dry eye, proinflammatory reactive aldehyde species (RASP) may contribute to ocular inflammation and changes in tear lipid composition

The double-blind, crossover, single-center Phase 2 clinical trial enrolled 56 patients with dry eye disease and evaluated the improvement in symptoms of 0.

Image source: Reference [1]

Dry eye is one of the most common chronic eye diseases, affecting the quality of life of millions of people, causing persistent stinging, burning, sensitivity to light, blurred vision and eye strain

References:

[1] Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®.

(Original abridged)